[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-416585-105":59,"doc-detail-416585-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","efficacy-and-safety-of-orelabrutinib-for-previously-treated-marginal-zone-lymphoma-abstract-and-retrospective-study-findings","Efficacy and Safety of Orelabrutinib for Previously Treated Marginal Zone Lymphoma - Abstract and Retrospective Study Findings","","A retrospective study evaluates the efficacy and safety of orelabrutinib monotherapy in Chinese patients with marginal zone B-cell lymphoma (MZL). MZL patients treated with orelabrutinib (n=30) were compared with a rituximab/rituximab plus bendamustine (R/BR, n=81) control, using propensity score matching. Clinical responses were observed in relapsed/refractory patients after non-rituximab-based chemotherapy, with lower lymphopenia and grade 3/4 adverse events for orelabrutinib.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/efficacy-and-safety-of-orelabrutinib-for-previously-treated-marginal-zone-lymphoma-abstract-and-retrospective-study-findings/416585/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/efficacy-and-safety-of-orelabrutinib-for-previously-treated-marginal-zone-lymphoma-abstract-and-retrospective-study-findings/416585.png","ImageObject",300,407,{"name":92,"@type":93},"Mary Man","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the purpose of the study on orelabrutinib in MZL?","Question",{"text":112,"@type":113},"The study aimed to investigate the efficacy and safety of orelabrutinib monotherapy in Chinese patients with marginal zone B-cell lymphoma.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the orelabrutinib and control groups formed and compared?",{"text":117,"@type":113},"Patients treated with orelabrutinib monotherapy (n=30) were compared with a control regimen (R/BR). Propensity score matching was used to match 30 MZL patients from the R/BR regimen group for comparison of efficacy and safety.",{"name":119,"@type":110,"acceptedAnswer":120},"What efficacy and safety outcomes differed between groups?",{"text":121,"@type":113},"Among patients with relapsed/refractory disease after non-rituximab-based chemotherapy, disease control rate, overall response rate, and complete response were not statistically significantly different. Safety showed lower lymphopenia and grade 3/4 adverse events in the orelabrutinib group.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},416585,1790741975,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},7421720224475,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Original Article J Hematol. 2025;14(6):297-306  \nEfficacy and Safety of Orelabrutinib for Previously Treated Marginal Zone Lymphoma  \nShi Lv Chena, Yu Fenga, b, Jiao Xuea, Shan Wanga, Shao Ling Wua, c  \nAbstract  \nBackground: This study aimed to investigate the efficacy and safety oforelabrutinib monotherapy in Chinese patients with marginal zone B-cell lymphoma (MZL) .  \nMethods: We conducted a retrospective analysis of MZL patients treated with orelabrutinib monotherapy (n = 30) or rituximab/rituximab plus bendamustine (R/BR) (n = 81) at the Affiliated Hospital of Qingdao University from January 1, 2019, to December 31, 2023. Orelabrutinib monotherapy was assigned to the experimental group. Propensity score matching (PSM) was applied to match 30 MZL patients treated with the R/BR regimen as a control group, comparing the efficacy and safety between the two groups.  \nResults: In both the orelabrutinib group and the control group, patients who developed relapsed or refractory (R/R) disease after non-rituximab/rituximab-based chemotherapy (non-R/R-CT) therapies (including anti-infective treatment and localized radiotherapy) achieved clinical responses. For 17 patients with R/R disease following R/R-CT treatment, no statistically significant differences were observed between the orelabrutinib group and the BR group in disease control rate (DCR) (82.35% vs. 88.23%, P = 1.00), overall response rate (ORR) (64.70% vs. 76.47%, P = 0.70), and complete response (CR) (17.64% vs. 29.41%, P = 0.68) . There was no statistically significant difference in 1-year event-free survival (EFS) (86.66%(95% confidence interval (CI): 68.27-94.77) vs. 83.33%(95% CI: 64.49 -92.70), P = 0.66). Hematologic adverse events (66.66% vs. 86.66%, P = 0.10), lymphopenia (6.66% vs. 40.00%, P \u003C 0.01), and grade 3/4 adverse events (10.00% vs. 33.33%, P = 0.03) were all lower in theorelabrutinib group compared to the control group. Neither group had patients who discontinued treatment due to adverse reactions.  \nConclusion: Orelabrutinib monotherapy in MZL possesses favora-  \nManuscript submitted October 28, 2025, accepted December 10, 2025 Published online December 30, 2025  \naDepartment of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China  \nbDepartment of Geriatrics, Deyang Hospital Affiliated to Chengdu University of Traditional Chinese Medicine, Sichuan, China  \ncCorresponding Author: Shao Ling Wu, Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.  \nEmail: [qdwushaoling@163.com](qdwushaoling@163.com)  \ndoi: [https://doi.org/10.14740/jh2149](https://doi.org/10.14740/jh2149)  \nble efficacy and safety in our study. Given the limited sample size, further clinical research with larger cohorts and extended follow-up is necessary.  \nKeywords: Lymphoma; B cell; Marginal zone; Bruton’s tyrosine kinase; Orelabrutinib; Safety  \nIntroduction  \nMarginal zone B-cell lymphoma (MZL) is an indolent subtype of non-Hodgkin’s lymphoma originating from the marginal zone of lymphoid tissue. It can be classified into three subtypes based on location: extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (EMZL/MALT), nodal marginal zone B-cell lymphoma (NMZL), and splenic marginal zone B-cell lymphoma (SMZL) [1] . Different types of MZL are treated in various ways. Anti-infective therapy is preferred for SMZL patients with hepatitis C virus (HCV) infection or EMZL with Helicobacter pylori (HP) . For asymptomatic patients with stage III/IV disease, observation can be considered [2, 3]. According to the latest National Comprehensive Cancer Network (NCCN) and Chinese Society of Clinical Oncology (CSCO) guidelines [4, 5], first-line treatment options for stage I/II MZL patients who fail anti-infection therapy typically involve rituximab or radiotherapy. For SMZL, a splenectomy is a viable option. For stage III/IV and relapsed or refractory (R/R) patients, treatment options primarily include","cbCaibd9WlD31Fz0","https://ap.wps.com/l/cbCaibd9WlD31Fz0","pdf",1149640,"English","# Abstract\n# Methods\n# Results\n# Conclusion\n# Keywords\n# Introduction","[{\"question\":\"What was the purpose of the study on orelabrutinib in MZL?\",\"answer\":\"The study aimed to investigate the efficacy and safety of orelabrutinib monotherapy in Chinese patients with marginal zone B-cell lymphoma.\"},{\"question\":\"How were the orelabrutinib and control groups formed and compared?\",\"answer\":\"Patients treated with orelabrutinib monotherapy (n=30) were compared with a control regimen (R/BR). Propensity score matching was used to match 30 MZL patients from the R/BR regimen group for comparison of efficacy and safety.\"},{\"question\":\"What efficacy and safety outcomes differed between groups?\",\"answer\":\"Among patients with relapsed/refractory disease after non-rituximab-based chemotherapy, disease control rate, overall response rate, and complete response were not statistically significantly different. Safety showed lower lymphopenia and grade 3/4 adverse events in the orelabrutinib group.\"}]","Efficacy and Safety of Orelabrutinib for Previously Treated Marginal Zone Lymphoma - Abstract and Retrospective Study Findings | PDF",1790605939,25]